Advertisement
RGEN vs WST
Which Stock Would AI Choose? Repligen Corporation (RGEN) vs. West Pharmaceutical Services, Inc. (WST) Stock Comparison
Key Takeaways
- Repligen Corporation (RGEN) specializes in bioprocessing technologies, while West Pharmaceutical Services, Inc. (WST) focuses on injectable drug delivery systems, both serving the biopharmaceutical supply chain.
- WST has a significantly larger market capitalization of approximately $20 billion compared to RGEN's $7.4 billion.
- Recent expansions highlight growth potential: RGEN opened a European training center, and WST expanded its Dublin facility for high-volume therapies.
- WST trades at a lower price-to-earnings (P/E) ratio of 41 versus RGEN's 153, suggesting relatively more attractive valuation.
- Both stocks exhibit volatility tied to biopharma demand, but WST has shown steadier recent rebound amid upcoming earnings expectations.
- Tickeron AI analysis leans toward WST for its momentum and catalysts in recent market activity.
Introduction
Repligen Corporation (RGEN) and West Pharmaceutical Services, Inc. (WST) operate in the life sciences tools sector, enabling biopharmaceutical production and drug delivery. This stock comparison analyzes their business models, recent performance, and market positioning amid ongoing demand for biologics and injectables. Traders seeking short-term momentum and investors eyeing long-term healthcare exposure may find value in evaluating relative strengths, such as growth drivers and valuation metrics, in the current market environment.
RGEN Overview and Recent Performance
Repligen Corporation (RGEN) develops and commercializes bioprocessing technologies, including filtration systems, chromatography resins, and process analytics tools sold to biopharma companies and contract manufacturers. In recent market activity, RGEN reported fourth-quarter revenue growth of 18% year-over-year to $198 million, driven by strong orders in bioprocessing consumables. The stock experienced pressure following earnings, declining about 13.5% in the subsequent weeks due to high expectations around profitability amid elevated valuations, with a trailing twelve months (TTM) P/E ratio near 153. Sentiment has shown signs of stabilization, bolstered by the opening of a new European Training and Innovation Center in Breda to enhance customer support. Trading near its 52-week midpoint, RGEN reflects broader biopharma supply chain dynamics influenced by manufacturing capacity expansions.
WST Overview and Recent Performance
West Pharmaceutical Services, Inc. (WST) designs and manufactures containment and delivery systems for injectable drugs, including stoppers, syringes, and self-injection platforms, primarily for pharmaceutical firms. Recent weeks have seen positive momentum, with shares rebounding amid facility expansions and anticipation for first-quarter earnings. The company announced an upgrade to its Dublin facility to support high-volume injectable therapies, including those for diabetes and obesity treatments. Fourth-quarter results beat expectations, with revenue and earnings per share (EPS) surpassing forecasts, contributing to a TTM P/E ratio of 41. Year-to-date performance remains modest, but recent price action indicates improving sentiment tied to demand for proprietary products in a recovering healthcare sector.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available models that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like swing trading, trend following, and multi-agent systems, with annualized returns ranging from +15% to +168%, win rates between 54% and 88%, and timeframes from 1 day to 55 days. For instance, bots targeting semiconductors or precious metals have delivered outsized short-term gains. Only the most suitable for prevailing market conditions earn a spot here, adapting to volatility in sectors like industrials and small caps. Traders can explore these automated tools to align with various risk profiles and time horizons—visit the page to evaluate live performance metrics.
Head-to-Head Comparison
Repligen (RGEN) and West (WST) both benefit from biopharma demand but differ in focus: RGEN upstream in bioprocessing versus WST downstream in delivery systems. Growth drivers include capacity expansions for both, yet WST’s scale—$3 billion TTM revenue versus $738 million—provides broader sector exposure. Recent momentum favors WST with its rebound and lower valuation, while RGEN faces risks from its premium P/E amid profitability scrutiny. Market sentiment reflects healthcare tailwinds, but WST offers relative stability through diversified contract manufacturing, contrasting RGEN’s specialized tech exposure.
Tickeron AI Verdict
Tickeron’s AI currently favors WST over RGEN, based on superior trend consistency, lower relative valuation, and tangible catalysts like facility expansions and earnings momentum. While RGEN holds potential in bioprocessing innovation, WST’s positioning suggests higher probability of near-term outperformance in volatile markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEN is a StrongBuy and WST is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RGEN’s FA Score shows that 0 FA rating(s) are green whileWST’s FA Score has 2 green FA rating(s).
- RGEN’s FA Score: 0 green, 5 red.
- WST’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RGEN’s TA Score shows that 6 TA indicator(s) are bullish while WST’s TA Score has 3 bullish TA indicator(s).
- RGEN’s TA Score: 6 bullish, 3 bearish.
- WST’s TA Score: 3 bullish, 5 bearish.
Price Growth
RGEN (@Pharmaceuticals: Other) experienced а -3.21% price change this week, while WST (@Pharmaceuticals: Other) price change was -0.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.83%. For the same industry, the average monthly price growth was -0.55%, and the average quarterly price growth was -14.44%.
Reported Earning Dates
RGEN is expected to report earnings on Aug 04, 2026.
WST is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-1.83% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| RGEN | WST | RGEN / WST | |
| Capitalization | 7.15B | 23.3B | 31% |
| EBITDA | 176M | 849M | 21% |
| Gain YTD | -22.696 | 20.034 | -113% |
| P/E Ratio | 139.20 | 44.08 | 316% |
| Revenue | 763M | 3.22B | 24% |
| Total Cash | 785M | 521M | 151% |
| Total Debt | 688M | 316M | 218% |
RGEN | WST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 47 | |
PRICE GROWTH RATING 1..100 | 46 | 13 | |
P/E GROWTH RATING 1..100 | 100 | 29 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
WST's Valuation (75) in the Medical Specialties industry is in the same range as RGEN (86) in the Biotechnology industry. This means that WST’s stock grew similarly to RGEN’s over the last 12 months.
WST's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that WST’s stock grew similarly to RGEN’s over the last 12 months.
WST's SMR Rating (47) in the Medical Specialties industry is somewhat better than the same rating for RGEN (90) in the Biotechnology industry. This means that WST’s stock grew somewhat faster than RGEN’s over the last 12 months.
WST's Price Growth Rating (13) in the Medical Specialties industry is somewhat better than the same rating for RGEN (46) in the Biotechnology industry. This means that WST’s stock grew somewhat faster than RGEN’s over the last 12 months.
WST's P/E Growth Rating (29) in the Medical Specialties industry is significantly better than the same rating for RGEN (100) in the Biotechnology industry. This means that WST’s stock grew significantly faster than RGEN’s over the last 12 months.
| RGEN | WST | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 64% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 51% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 68% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 67% |
| Advances ODDS (%) | 8 days ago 74% | 2 days ago 68% |
| Declines ODDS (%) | 2 days ago 81% | 12 days ago 58% |
| BollingerBands ODDS (%) | N/A | 2 days ago 58% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 61% |
Advertisement
RGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | -4.05% | ||
| DHR - RGEN | 67% Closely correlated | +0.58% | ||
| A - RGEN | 65% Loosely correlated | -0.45% | ||
| BIO - RGEN | 60% Loosely correlated | -0.47% | ||
| MTD - RGEN | 59% Loosely correlated | +1.68% | ||
| TMO - RGEN | 58% Loosely correlated | -0.13% | ||
More | ||||
WST and
Correlation & Price change
A.I.dvisor indicates that over the last year, WST has been loosely correlated with STVN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if WST jumps, then STVN could also see price increases.
| Ticker / NAME | Correlation To WST | 1D Price Change % | ||
|---|---|---|---|---|
| WST | 100% | +0.54% | ||
| STVN - WST | 54% Loosely correlated | -3.42% | ||
| RGEN - WST | 34% Loosely correlated | -4.05% | ||
| QDEL - WST | 33% Loosely correlated | -9.51% | ||
| XRAY - WST | 32% Poorly correlated | -1.74% | ||
| CAPN - WST | 32% Poorly correlated | N/A | ||
More | ||||